Last reviewed · How we verify
NCT05362604: DANATRESIA
Prenatal Diagnosis of the Fetal Esophageal or Intestinal Atresia
trial testing scheduled delivery at a tertiary center in Antenatal Management of the Fetal Gastrointestinal Atresia in 51 participants. Completed in 7 February 2022.
7 February 2022
Quick facts
| Lead sponsor | Poitiers University Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 51 |
| Start date | 1 April 2021 |
| Primary completion | 7 February 2022 |
| Estimated completion | 7 February 2022 |
| Sites | 1 location across France |
Drugs / interventions tested
- scheduled delivery at a tertiary center
Conditions studied
- Antenatal Management of the Fetal Gastrointestinal Atresia — all drugs for Antenatal Management of the Fetal Gastrointestinal Atresia →
Sponsor
Poitiers University Hospital
Who can join
Adults 18 to 50, any sex, with Antenatal Management of the Fetal Gastrointestinal Atresia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Aim- to investigate how prenatal diagnosis of fetal esophageal or intestinal atresia impacts obstetric and neonatal outcomes. Methods- This was a retrospective cohort study at a single center. The study population comprised 51 consecutive pregnancies, including 29 mothers (57%) and their fetuses affected by prenatally diagnosed fetal esophageal or intestinal atresia, and 22 mothers (43%) and their babies with postnatally diagnosed fetal esophageal or intestinal atresia.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05362604
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Poitiers University Hospital trials
Trials by the same sponsor.
- NCT07350291 — Evaluation of the Diagnostic Capabilities of Saliva Samples From Pediatric Patients, Promoting Active Involvement of the · NA · not yet recruiting
- NCT07411651 — Confirmation of the Link Between Endocrine Disruptors Exposure and Breast Cancer and Identification of Biological Respon · NA · not yet recruiting
- NCT07463963 — Relevance of the Urine Bacterial Culture Performed Before TransUrethral Resection of the Bladder for Post-operative Febr · NA · not yet recruiting
- NCT07475442 — Prognostic Factors of Hospitalization for Patients Aged 75 and Over in Emergency Department in France - Monocentric Retr · not yet recruiting
- NCT07412717 — The Efficacy of Combining Music Intervention With Nicotine Replacement Therapy to Reduce Smoking Craving, Among Healthca · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05362604 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Poitiers University Hospital
- Last refreshed: 5 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05362604.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing